Evidence map›Paper›PMID 28827404›Full record

ArticleDiabetes care2017

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.

Girish N Nadkarni, Rocco Ferrandino, Alexander Chang, Aditya Surapaneni, Kinsuk Chauhan, Priti Poojary, Aparna Saha, Bart Ferket, Morgan E Grams, Steven G Coca

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 9 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 9 syntheses or guidelines pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  12. Review
  13. SGLT2 inhibitors and acute kidney injury.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  14. Review
  15. Article
  16. Review
  17. Gliflozins in hypertension: basic mechanisms and clinical insights.American journal of physiology. Renal physiology · 2025
    Review
  18. Article
  19. Article
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Girish N NadkarniDepartment of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY girish.nadkarni@mountsinai.org steven.coca@mssm.edu.ORCID 0000-0001-6319-4314
Rocco FerrandinoIcahn School of Medicine at Mount Sinai, New York, NY.
Alexander ChangDivision of Nephrology, Geisinger Medical Center, Danville, PA.
Aditya SurapaneniDivision of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD.
Kinsuk ChauhanDepartment of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY.
Priti PoojaryDepartment of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY.
Aparna SahaDepartment of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY.
Bart FerketInstitute for Healthcare Delivery Science, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.
Morgan E GramsDivision of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-4430-6023
Steven G CocaDepartment of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY girish.nadkarni@mountsinai.org steven.coca@mssm.edu.
Icahn School of Medicine at Mount Sinai · USJohns Hopkins University · USGeisinger Medical Center · US

Funding

NCATS NIH HHS TL1 TR001434NIDDK NIH HHS K23 DK106515NIDDK NIH HHS K23 DK107908NIDDK NIH HHS R01 DK096549NIDDK NIH HHS U01 DK106962
6 · The paper itself

Abstract

objectiveSodium-glucose cotransporter-2 (SGLT2) inhibitors are new medications that improve cardiovascular and renal outcomes in patients with type 2 diabetes (T2D). However, the Food and Drug Administration has issued alerts regarding increased acute kidney injury (AKI) risk with canagliflozin and dapagliflozin. We aimed to assess the real-world risk of AKI in new SGLT2 inhibitor users in two large health care utilization cohorts of patients with T2D. RESEARCH DESIGN AND

methodsWe used longitudinal data from the Mount Sinai chronic kidney disease registry and the Geisinger Health System cohort. We selected SGLT inhibitor users and nonusers (patients with T2D without SGLT2 inhibitor prescription). We determined AKI by the KDIGO (Kidney Disease: Improving Global Outcomes) definition (AKI

resultsWe identified 377 SGLT2 inhibitor users and 377 nonusers in the Mount Sinai cohort, of whom 3.8 and 9.7%, respectively, had an AKI

conclusionsOur findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with T2D in two large health systems.

Indexed as

Acute Kidney InjuryAgedBenzhydryl CompoundsBlood PressureBody Mass IndexCanagliflozinCholesterolDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlucosidesHemoglobinsHumansHypoglycemic AgentsIncidenceKidneyBenzhydryl CompoundsCanagliflozinCholesteroldapagliflozinGlucosidesHemoglobinsHypoglycemic AgentsSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID28827404
PMCPMC5652593
OpenAlexW2749798950

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.